Picture offshore wind farm

Open Access research that is improving renewable energy technology...

Strathprints makes available scholarly Open Access content by researchers across the departments of Mechanical & Aerospace Engineering (MAE), Electronic & Electrical Engineering (EEE), and Naval Architecture, Ocean & Marine Engineering (NAOME), all of which are leading research into aspects of wind energy, the control of wind turbines and wind farms.

Researchers at EEE are examining the dynamic analysis of turbines, their modelling and simulation, control system design and their optimisation, along with resource assessment and condition monitoring issues. The Energy Systems Research Unit (ESRU) within MAE is producing research to achieve significant levels of energy efficiency using new and renewable energy systems. Meanwhile, researchers at NAOME are supporting the development of offshore wind, wave and tidal-current energy to assist in the provision of diverse energy sources and economic growth in the renewable energy sector.

Explore Open Access research by EEE, MAE and NAOME on renewable energy technologies. Or explore all of Strathclyde's Open Access research...

Peroral amphotericin B polymer nanoparticles lead to comparable or superior in vivo antifungal activity to that of intravenous Ambisome® or Fungizone™

Italia, Jagdishbhai L and Sharp, Andrew and Carter, Katharine C and Warn, Peter and Kumar, M N V Ravi (2011) Peroral amphotericin B polymer nanoparticles lead to comparable or superior in vivo antifungal activity to that of intravenous Ambisome® or Fungizone™. PLoS One, 6 (10).

[img] PDF (Italia_etal_PLoSOne2011)
Italia_etal_PLoSOne2011.pdf
Final Published Version
License: Creative Commons Attribution 4.0 logo

Download (1MB)

Abstract

Background: Despite advances in the treatment, the morbidity and mortality rate associated with invasive aspergillosis remains unacceptably high (70–90%) in immunocompromised patients. Amphotericin B (AMB), a polyene antibiotic with broad spectrum antifungal activity appears to be a choice of treatment but is available only as an intravenous formulation; development of an oral formulation would be beneficial as well as economical. Methodology: Poly(lactide-co-glycolode) (PLGA) nanoparticles encapsulating AMB (AMB-NPs) were developed for oral administration. The AMB-NPs were 113±20 nm in size with ~70% entrapment efficiency at 30% AMB w/w of polymer. The in vivo therapeutic efficacy of oral AMB-NPs was evaluated in neutropenic murine models of disseminated and invasive pulmonary aspergillosis. AMB-NPs exhibited comparable or superior efficacy to that of Ambisome® or Fungizone™ administered parenterally indicating potential of NPs as carrier for oral delivery. Conclusions: The present investigation describes an efficient way of producing AMB-NPs with higher AMB pay-load and entrapment efficiency employing DMSO as solvent and ethanol as non-solvent. The developed oral formulation was highly efficacious in murine models of disseminated aspergillosis as well as an invasive pulmonary aspergillosis, which is refractory to treatment with IP Fungizone™and responds only modestly to AmBisome®.